Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons and cognition.

X Montalban1, J Rio

  • 1Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. xavier.montalban@unic-em.com

Journal of the Neurological Sciences
|April 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of the type of volatile anesthetic on the development of acute kidney injury after endovascular repair of aortic aneurysm: a randomized controlled trial (DESEVAR study).

Frontiers in pharmacology·2025
Same author

Synthetic MRI in Progressive MS: Associations with Disability.

AJNR. American journal of neuroradiology·2025
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

Neurologia·2024
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

Revista de neurologia·2023
Same journal

Distinguishing drug-target effects from natural lipid variation and incorporating imaging outcomes in Mendelian randomisation studies of multiple sclerosis.

Journal of the neurological sciences·2026
Same journal

Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study.

Journal of the neurological sciences·2026
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
See all related articles

Interferon beta (IFNbeta) effects on cognitive impairment in multiple sclerosis (MS) are not fully understood. This review examines current data and suggests future research directions for IFNbeta

Area of Science:

  • Neuroimmunology
  • Neurology
  • Clinical Trials

Background:

  • Cognitive impairment is a common symptom in multiple sclerosis (MS).
  • The impact of immunomodulating drugs, particularly interferon beta (IFNbeta), on MS-related cognitive deficits requires further investigation.
  • Existing data on IFNbeta's effect on cognition in MS are inconclusive.

Purpose of the Study:

  • To review the current evidence on the effects of interferon beta (IFNbeta) on cognitive function across various clinical forms of multiple sclerosis (MS).
  • To identify gaps in knowledge and propose future directions for clinical trials investigating IFNbeta and cognition in MS.

Main Methods:

  • Literature review of studies examining interferon beta (IFNbeta) treatment and cognitive outcomes in multiple sclerosis (MS) patients.

Related Experiment Videos

  • Analysis of data across different clinical subtypes of MS.
  • Synthesis of findings to inform future research strategies.

    • Main Results:

    • The precise impact of interferon beta (IFNbeta) on neuropsychological aspects of multiple sclerosis (MS) remains incompletely elucidated.
    • Current data are not conclusive regarding the efficacy of IFNbeta in improving or preventing cognitive decline in MS.
    • Variability in study designs and patient populations may contribute to the inconclusive findings.

    Conclusions:

    • Further well-designed clinical trials are necessary to definitively assess the role of interferon beta (IFNbeta) in managing cognitive impairment in multiple sclerosis (MS).
    • Future research should consider specific clinical phenotypes and standardized cognitive assessments.
    • Understanding IFNbeta's neurobiological mechanisms is crucial for optimizing treatment strategies for MS-related cognitive dysfunction.